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Case Report
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To describe the clinical and optical coherence tomography (OCT) features of a macular hole (MH) or its precursor 
lesion in patients treated with systemic antiestrogen agents. We reviewed the medical history of the patient, oph-
thalmic examination, and both fundus and OCT findings. Three female patients receiving antiestrogen therapy 
sought treatment for visual disturbance. All of the patients showed foveal cystic changes with outer retinal defect 
upon OCT. Visual improvement was achieved through surgery for the treatment of MH in two patients. Antiestrogen 
therapy may result in MH or its precursor lesion, in addition to perifoveal refractile deposits. OCT examination would 
be helpful for early detection in such cases.
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Tamoxifen is an oral nonsteroidal antiestrogen drug 
which is most commonly used at low dosages (20 mg daily) 
for the adjuvant treatment of breast cancer [1]. Toremifen is 
a triphenylethylene derivative which was developed in an 
effort to improve the therapeutic-to-toxic ratio of 
tamoxifen. Tamoxifen has proven to be relatively free of se-
rious adverse effects, but some retinal abnormalities have 
been reported―most notably refractile perifoveal opacities, 
cystoid macular edema, and retinal pigment epithelial ab-
normalities [1,2]. While some cases of the formation of 
macular holes (MH) in association with tamoxifen have 
been reported [3,4], as of yet, there has been no report ad-
dressing the formation of MH in a patient taking toremifen. 
In this study, we describe three cases of MH or its precursor 
lesion in patients treated with systemic antiestrogen agents.
Case Report
Case 1 
A 36-year-old woman was referred to our clinic with a di-
agnosis of foveal cyst OU, which were detected upon fun-
dus examination in June 2005. The patient had complained 
of decreased vision for several months. Her past medical 
history included a radical mastectomy for breast carcinoma 
in March 2003. After mastectomy, she had been started on 
toremifen, at a daily dose of 40 mg. Her visual acuity (VA) 
was 20/32 OD and 20/70 OS. No anterior segment abnor-
malities were detected. Fundus examination revealed cystic 
changes in the foveal center OU (Fig. 1A and 1B). Optical 
coherence tomography (OCT) showed a focal defect of the 
outer retinal layer OU (Fig. 1C and 1D). She was diagnosed 
with symptomatic impending MH (Gass, stage Ib). In July 
2005, her left eye was treated via pars plana vitrectomy, in-
ternal limiting membrane (ILM) peeling, and SF6 gas tam-
ponade, after obtaining informed consent. The MH was suc-
cessfully closed (Fig. 1F). In October 2005, fundus exami-
nation revealed aggravated cystic changes in the foveal cen-
ter OD. Her VA was 20/125 OD and 20/32 OS at that time. 
An OCT scan of her right eye revealed an enlarged outer 
retinal defect (Fig. 1E). Her right eye was also treated via 
pars plana vitrectomy, ILM peeling, and SF6 gas 
tamponade. She had discontinued her toremifen regimen in 
October 2005. In January 2006, a fundus examination and 
OCT scan revealed the successful closure of the holes OU 
(Fig. 1G and 1H), and her VA was improved to 20/30 OD 
and to 20/25 OS.
Case 2
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Fig. 1. Fundus photograph and optical coherence tomographic images of both eyes of patient 1. (A,C) At presentation, the image shows fo-
veal cystic changes with outer retinal defect in the patient’s right eye. (B,D) At presentation, the image shows a stage 1b macular hole in 
the left eye. (E) The enlargement of outer foveal defect is noted in the right eye 4 months after initial presentation, with further deterioration 
of vision. (F) However, improved foveal contour and vision is noted after macular hole surgery in the left eye. (G,H) The closure of mac-
ular hole is achieved in both eyes after completing the surgery in both eyes.
a six-month history of progressive visual loss and central 
scotoma OD. Four years ago, she had undergone a radical 
mastectomy for breast carcinoma. She was treated with a 
cumulative dose of 55 g toremifen over 46 months after sur-
gical resection. VA was 20/125 OD. Fundus examination of 
her right eye revealed a cystic change in the foveal center 
(Fig. 2A). Additionally, a focal defect of the outer retinal 
layer was noted on OCT examination (Fig. 2B). Surgery for 
the treatment of MH was conducted two weeks after her ini-
tial visit. The MH was sealed, resulting in an improvement 
of VA to 20/63 (Fig. 2C).
Case 3
A 51-year-old woman had a chief symptom of decreased 
VA OS, which had developed several months ago. In Korean J Ophthalmol Vol.24, No.5, 2010
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Fig. 2. Right eye of patient 2. Fundus photographic image (A) shows foveal cystic change, and the optical coherence tomographic image 
(B) shows a focal outer retinal defect at initial presentation. The contour of the fovea returns to normal after macular hole surgery.
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Fig. 3. Fundus photographic images of both eyes in patient 3. At 
initial presentation, small multiple refractile deposits are noted in 
both of the patient’s eyes (A,B). Optical coherence tomographic 
(OCT) scan of the macula shows no specific abnormality in the 
right eye (C); however, a focal defect of the outer retinal layer is 
noted in the left eye (D). No interval change in OCT findings is 
noted after 5 months (E).
November 2008, she was referred to us due to a macular ab-
normality. In February 2001, she underwent a modified 
radical mastectomy for invasive ductal cancer (T2N0M0, 
stage IIa). She was also treated with 2.5 mg tamoxifen on a 
daily basis from April 2007 to March 2008. She has dis-
continued her tamoxifen regimen due to vaginal bleeding. 
Upon examination, VA was 20/20 OD and 20/30 OS. 
Fundus examination showed refractile deposits in both SE Chung, et al. Estrogen Antagonist and Macular Hole
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macular areas (Fig. 3A and 3B). OCT showed a normal OD; 
however, a focal defect of the outer retinal layer was ob-
served in the fovea OS (Fig. 3C and 3D). Additionally, the 
patient has been put on a follow-up schedule of regular 
3-month intervals. In April 2009, we noted no changes in 
the OCT findings OU (Fig. 3E). 
Discussion
All patients referenced herein experienced visual dis-
turbances associated with MH precursor lesions. Additionally, 
visual improvements were achieved via MH surgery. 
Although previous reports of ocular abnormalities have 
raised some concerns regarding antiestrogen use, sig-
nificant deterioration of vision is rare, at least in cases of 
short-term administration. 
Idiopathic MH occurs predominantly in old women 
(74%) [5]. Case 2 coincided with the demographic profile 
of idiopathic MH. Furthermore, the lesion developed unilat-
erally in this case. Thus, it remains uncertain as to whether 
there was a real association with the administration of anti-
estrogen agents. However, case 1 was much younger than the 
idiopathic MH patients, and evidenced bilateral involvement. 
Additionally, in case 3, typical refractile deposition was 
noted in both eyes, along with unilateral MH precursor 
lesion.
The mechanisms of MH formation following admini- 
stration of an antiestrogen agent are merely speculative. It is 
worth noting that idiopathic MHs predominantly occur in 
postmenopausal women, and current estrogen users were 
found to be at reduced risk for developing MH [6]. Elevated 
serum fibrinogen levels have been noted in menopausal 
women and may induce a rapid deceleration of blood flow 
in the submacular choroid, eventually rendering foveal tis-
sue susceptible to vitreous traction [6].
 As our patients were 
treated with antiestrogen agents over a long period, the de-
velopment of MH precursor lesions would be related to 
their depleted plasma estrogen. 
In one report of eyes evidencing tamoxifen retinopathy, 
foveal cystoid space and the interruption of the photo-
receptor line, observed upon OCT, was described [2]. It re-
mains uncertain as to whether the case was actually repre-
sentative of an MH precursor lesion. In another report, MH 
in 4.12% of female patients were associated with current 
use of tamoxifen [3]. The natural course of MH or its pre-
cursor lesion after systemic antiestrogen administration re-
mains unknown. However, recognizing the development of 
MH appears worthwhile, because, as was noted in our cas-
es, vision can be restored via surgical intervention. 
Physicians should be aware of and concerned about this ret-
inal complications. Periodic OCT examinations after the 
systemic administration of antiestrogen, especially in cases 
in which the patient complains of visual deterioration or 
metamorphopsia, would be helpful for early identification.
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